<![CDATA[Gedatolisib Triplet Shows Significant PFS Benefit in HR+/HER2– Breast Cancer]]>
Gedatolisib (PF-05212384; Celcuity, Inc) plus fulvestrant (Faslodex; AstraZeneca) and palbociclib (Ibrance; Pfizer Inc) met its primary end point of median progression-free survival (mPFS) in the VIKTORIA-1 trial (NCT05501886). The data were presented at …